- Home
- LPCN vs DKI Comparison
LPCN vs DKI Comparison
Compare LPCN & DKI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPCN
- DKI
- Stock Information
- Founded
- LPCN 1997
- DKI 2018
- Country
- LPCN United States
- DKI Hong Kong
- Employees
- LPCN N/A
- DKI N/A
- Industry
- LPCN Biotechnology: Pharmaceutical Preparations
- DKI
- Sector
- LPCN Health Care
- DKI
- Exchange
- LPCN Nasdaq
- DKI Nasdaq
- Market Cap
- LPCN 13.8M
- DKI 11.9M
- IPO Year
- LPCN N/A
- DKI 2025
- Fundamental
- Price
- LPCN $3.18
- DKI $0.40
- Analyst Decision
- LPCN Strong Buy
- DKI
- Analyst Count
- LPCN 1
- DKI 0
- Target Price
- LPCN $7.00
- DKI N/A
- AVG Volume (30 Days)
- LPCN 54.7K
- DKI 217.6K
- Earning Date
- LPCN 11-06-2025
- DKI 12-05-2025
- Dividend Yield
- LPCN N/A
- DKI N/A
- EPS Growth
- LPCN N/A
- DKI N/A
- EPS
- LPCN N/A
- DKI 26.19
- Revenue
- LPCN $4,322,693.00
- DKI $10,204,329.00
- Revenue This Year
- LPCN N/A
- DKI N/A
- Revenue Next Year
- LPCN N/A
- DKI N/A
- P/E Ratio
- LPCN N/A
- DKI $0.01
- Revenue Growth
- LPCN N/A
- DKI 100.46
- 52 Week Low
- LPCN $2.52
- DKI $0.37
- 52 Week High
- LPCN $5.50
- DKI $15.00
- Technical
- Relative Strength Index (RSI)
- LPCN 61.21
- DKI N/A
- Support Level
- LPCN $3.07
- DKI N/A
- Resistance Level
- LPCN $3.32
- DKI N/A
- Average True Range (ATR)
- LPCN 0.20
- DKI 0.00
- MACD
- LPCN 0.06
- DKI 0.00
- Stochastic Oscillator
- LPCN 65.82
- DKI 0.00
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
About DKI DarkIris Inc. Class A Ordinary Shares
Darkiris Inc is a comprehensive technology enterprise engaged in the development, publishing and operating of mobile digital games via various third-party digital storefronts. Its activities encompass including game design, programming and graphics, as well as distribution and operation of mobile games on various platforms. Its core product offerings are Games Development; develop, market and distribute its self-developed mobile games; and Games Publishing and Operation. It publish and operate its self-developed mobile games and mobile games it license from other game developers.